May 2026– date –
-
OCSiAl Launches Advanced SWCNTs for High-Performance Electrodes and Next-Gen Battery Systems
OCSiAl ルクセンブルク Overview OCSiAl, a global leader in single-walled carbon nanotube (SWCNT) technology, has unveiled a new suite of SWCNT products optimized for high-performance battery electrodes and emerging chemistries. These inno... -
Fujikura and MIT Introduce ‘Implosion Carving’: A New Paradigm for 3D Nanofabrication
株式会社フジクラのプレスリリース Japan Overview Fujikura, in collaboration with MIT, has unveiled "Implosion Carving (ImpCarv)," a groundbreaking 3D nanofabrication technique published in Nature Photonics. This method precisely sculpts i... -
Samsung Unveils Next-Gen Odyssey Gaming Monitors with Penta Tandem QD-OLED, Including Industry-First 6K Model
Samsung South Korea Overview Samsung has launched an advanced lineup of Odyssey gaming monitors, highlighted by the new 27-inch and 32-inch Odyssey OLED G8 (G80SH) models, featuring 4K resolution and 240Hz refresh rates. These displays i... -
Samsung Display Elevates QD-OLED Performance with Penta Tandem Technology: Achieving 320Hz, 1300 Nits, and Doubled Lifespan
FlatpanelsHD デンマーク Overview Samsung Display has integrated its advanced Penta Tandem technology into its 27-inch 1440p QD-OLED panels, delivering a significant leap in display performance. This enhancement boosts refresh rates to 32... -
Vertex Pharmaceuticals Secures CASGEVY Reimbursement Agreement in Germany for Sickle Cell Disease and Beta Thalassemia
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced a reimbursement agreement in Germany for CASGEVY (exa-cel), a groundbreaking gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassem... -
iPSC-Derived Retinal Sheet Transplantation for Retinitis Pigmentosa: Clinical Trial Validates Long-Term Safety and Engraftment
臨床研究等提出・公開システム (jRCT) Japan Overview A pioneering clinical study (jRCTa050200027) conducted by Kobe City Eye Center Hospital has concluded, affirming the long-term safety and engraftment of allogeneic iPSC-derived retinal s... -
SelectBIO to Host Lipid Nanoparticles (LNPs) Asia/Pacific 2026: Driving mRNA Delivery Innovations
SelectBIO Conferences UK Overview SelectBIO Conferences will host the 'Lipid Nanoparticles (LNPs) Asia/Pacific 2026' event, focusing on LNPs, extracellular vesicles, exosomes, and Japanese research. The conference will primarily address ... -
The Future of Healing: Gene Therapy in 2026 Navigates CRISPR Advances and Access Challenges
薬事日報 Japan Overview By 2026, gene therapy is undergoing a paradigm shift, moving towards direct repair or replacement of disease-causing genes. CRISPR-based in vivo editing shows early clinical promise, pushing the vision of single-i... -
iPSC-Derived Cell Therapy Pipeline 2026: From Disease Modeling to Expanding Clinical Applications
BioInformant USA Overview As of 2026, the iPSC-derived cell therapy pipeline shows rapid advancements in disease modeling and drug discovery, though broad clinical use in human patients still faces challenges. iPSC-derived cells hold imm... -
iRegene Therapeutics’ NouvNeu001 Secures Dual FDA Expedited Designations: A New Regulatory Milestone for iPSC Therapies
RegMedNet UK Overview iRegene Therapeutics announced its allogeneic iPSC-derived therapy, NouvNeu001, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for Parkinson's disease, following its prior Fast ...
